Revised response criteria for polycythemia vera and essential thrombocythemia: An ELN and IWG-MRT consensus project

Blood

Volumn 121, Issue 23, 2013, Pages 4778-4781

  Barosi, Giovanni ^a   Mesa, Ruben ^b   Finazzi, Guido ^c   Harrison, Claire ^d   Kiladjian, Jean Jacques ^e   Lengfelder, Eva ^f   McMullin, Mary F ^g   Passamonti, Francesco ^h   Vannucchi, Alessandro M ⁱ   Besses, Carlos ^j   Gisslinger, Heinz ^k   Samuelsson, Jan ^l   Verstovsek, Srdan ^m   Hoffman, Ronald ⁿ   Pardanani, Animesh ^o   Cervantes, Francisco ^p   Tefferi, Ayalew ^o   Barbui, Tiziano ^c  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b MAYO CLINIC   (United States)

^c PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e SAINT LOUIS HOSPITAL   (France)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^h OSPEDALE DI CIRCOLO   (Italy)

ⁱ UNIVERSITY OF FLORENCE   (Italy)

^j HOSPITAL DEL MAR   (Spain)

^k MEDICAL UNIVERSITY OF VIENNA   (Austria)

^l STOCKHOLM SÖDER HOSPITAL   (Sweden)

^m UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁿ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^o MAYO CLINIC   (United States)

^p UNIVERSITY OF BARCELONA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG; ANTITHROMBOCYTIC AGENT;

ARTICLE; BONE MARROW BIOPSY; CLINICAL PRACTICE; DISEASE COURSE; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; MEDICAL RESEARCH; MYELOPROLIFERATIVE NEOPLASMAN ASSESSMENT TOTAL SYMPTOM SCORE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; SYMPTOM ASSESSMENT; THROMBOCYTE COUNT; THROMBOCYTHEMIA; TREATMENT RESPONSE; CONSENSUS; INTERNATIONAL COOPERATION; MEDICAL SOCIETY; MORTALITY; PRACTICE GUIDELINE; STANDARD;

CONSENSUS; HUMANS; INTERNATIONAL AGENCIES; PLATELET AGGREGATION INHIBITORS; POLYCYTHEMIA VERA; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; THROMBOCYTHEMIA, ESSENTIAL;

MLCS; MLOWN;

EID: 84881065384     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-478891     Document Type: Article

References (16)

1. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113(20):4829-4833.
2. Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the histone-deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010;150(4):446-455.
3. Gisslinger H, Kralovics R, Gisslinger B, et al. AOP2014, a novel Peg-proline-interferon alpha-2b with improved pharmacokinetic properties, is safe and well tolerated and shows promising efficacy in patients with polycythemia vera (PV) [abstract]. Blood. 2012;120(21):175.
4. Verstovsek S, Passamonti F, Rambaldi A, et al. Long-term efficacy and safety results from a Phase II study of ruxolitinib in patients with polycythemia vera [abstract]. Blood. 2012; 120(21):804.
5. Angona A, Bellosillo B, Alvarez-Larrán A, et al. Genetic predisposition to molecular response in patients with myeloproliferative neoplasms treated with hydroxycarbamide [abstract]. Blood. 2012; 120(21):1738.
6. Yassin MA, Al-Dewik N, Rafii El-Ayoubi H. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in essential thrombocythemia [abstract]. Blood. 2012;120(21):1743.
7. Barosi G, Tefferi A, Barbui T; ad hoc committee ‘Definition of clinically relevant outcomes for contemporarily clinical trials in Ph-neg MPNs’. Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients? Leukemia. 2012;26(5):1148-1149.
8. Carobbio A, Finazzi G, Antonioli E, et al. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. Blood. 2010;116(7): 1051-1055.
9. Alvarez-Larrán A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012;119(6):1363-1369.
10. Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs [published correction appears in J Clin Oncol. 2012;30(36):4590]. J Clin Oncol. 2012;30(33):4098-4103.
11. Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401-408.
12. Barosi G, Mesa RA, Thiele J, et al; International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Proposed criteria for the diagnosis of post-polycythemia vera and postessential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437-438.
13. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008.
14. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8): 3065-3072.
15. Bench AJ, White HE, Foroni L, et al. Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. Br J Haematol. 2013; 160(1):25-34.
16. Kiladjian JJ, Massé A, Cassinat B, et al; French Intergroup of Myeloproliferative Neoplasms (FIM). Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia. 2010;24(8):1519-1523.